BeOne Medicines Ltd. (ONC) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $34.83B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Pharmaceuticals |
| Country | US | CEO | John V. Oyler |
| IPO Date | 2016-02-02 | CAGR | 67.26% |
| Employees | 12,000 | Website | beonemedicines.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $30.98B | P/E | 72.91 | Forward P/E | 33.66 | PEG | — |
| P/S | 5.04 | P/B | 8.45 | P/CF | 31.06 | P/FCF | 26.42 |
| Sales | $5.74B | Sales 1Y | 37.44% | Sales 3Y | 268.58% | Sales 5Y | 565.27% |
| EPS | $4.47 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | 1.02% | EPS QoQ | 275% | Sales QoQ Avg | 8.05% | EPS QoQ Avg | 2508.63% |
| Gross Margin | 87.17% | Operating Margin | 11.96% | Profit Margin | 8.93% | ROCE | 10.2% |
| ROA | 6% | ROE | 12% | Altman Z Score | 5.82 | Piotroski Score | 7 |
| Current Ratio | 3.64 | Quick Ratio | 3.27 | Cash Ratio | 2.67 | Op. CF Ratio | 0.11 |
| Debt/Equity | 0.43 | Debt/Assets | 0.13 | Lt Debt/Equity | 0.21 | Lt Debt/Cap. | 0.27 |
| Intrst Cov. | 12.79 | Inventory Turnover | 1.08 | Asset Turnover | 0.67 | Receivables Turnover | 6.06 |
| Enterprise Value | $30.98B | P/E Ratio | 72.91 |
| Forward P/E | 33.66 | PEG Ratio | — |
| P/S Ratio | 5.04 | P/B Ratio | 8.45 |
| P/CF Ratio | 31.06 | P/FCF Ratio | 26.42 |
| EPS | $4.47 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 37.44% | Gross Margin | 0.87% |
| Operating Margin | 0.12% | Profit Margin | 0.09% |
| ROE | 0.12% | ROA | 0.06% |
| ROCE | 0.1% | Current Ratio | 3.64 |
| Quick Ratio | 3.27 | Cash Ratio | 2.67 |
| Debt/Equity | 0.43 | Interest Coverage | 12.79 |
| Altman Z Score | 5.82 | Piotroski Score | 7 |
BeOne Medicines Ltd. (ONC) valuation & financials
BeOne Medicines Ltd. (ONC) has a market capitalization of $34.83B and trades at a price-to-earnings ratio of 72.9. It operates in the Healthcare sector (Medical - Pharmaceuticals).
BeOne Medicines Ltd.'s revenue grew +37.4% over the last year.
BeOne Medicines Ltd.'s next earnings report is scheduled for August 5, 2026 before market open; analysts estimate EPS of $1.57.
BeOne Medicines Ltd. (ONC) — frequently asked questions
When does BeOne Medicines Ltd. (ONC) report earnings next?
BeOne Medicines Ltd. is expected to report earnings on August 5, 2026 before market open. Analysts estimate EPS of $1.57.
What is BeOne Medicines Ltd.'s market cap?
BeOne Medicines Ltd. (ONC) has a market capitalization of $34.83B.
What is ONC's P/E ratio?
BeOne Medicines Ltd. trades at a price-to-earnings ratio of 72.9, with trailing twelve-month EPS of $4.47.
How fast is BeOne Medicines Ltd. growing?
BeOne Medicines Ltd.'s revenue grew +37.4% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)